Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Retina, Imaging & Diagnostics

DIY OCT

AMD may well be treatable with anti-VEGF injections, but it comes at a cost to the patient: regular visits to the ophthalmologist’s office for disease monitoring with OCT. For elderly and visually impaired patients who require travel assistance, these frequent appointments can represent a further burden on their relatives – or their finances. A team from Universitätsklinikum Schleswig-Holstein, Kiel, and Medical Laser Center, Lübeck, Germany, have a potential solution in the form of a hand-held OCT device for home-monitoring of patients with retinal disease.

Given today’s advanced – and costly – OCT systems, what does a home-care setup look like, and how can it be achieved? “For a device to be used by the patients themselves, it needs to be small and low-cost,” explains Claus von der Burchard, Research Fellow at Universitätsklinikum Schleswig-Holstein. “To get there, we’ve had to make some compromises on image quality.” The result is off-axis full-field time-domain OCT (1). Von der Burchard explains: “We focused on reducing the scan area to 3 x 3 mm and using a full-field system which illuminates the whole field.” According to von der Burchard, the 3 x 3 images provide good sensitivity and specificity for monitoring subretinal and intraretinal fluid volume, and the full-field approach increases visual quality. “The design is also very simple, needing only a standard light source – rather than swept-source – and a regular, low-cost USB camera.”

Figure 1. a. The current prototype for the hand-held device. Credit: Universitätsklinikum Schleswig-Holstein, Kiel, and Medical Laser Center, Lübeck, Germany.
Figure 1. b. SD-OCT image (left) and off-axis full-field time domain OCT image (right) from a patient with AMD (84 years old; visual acuity, 20/80). The red arrow depicts subretinal fluid which is visible on images from both the clinical and hand-held device.

Though the team are still in the research phase, they have tested their device – alongside spectral-domain (SD)-OCT – in 10 patients with retinal disease (including AMD and retinal vein occlusion), and have shown that it can acquire clinically-useful images (Figure 1). “Even though the image quality is not quite as good as clinical OCT systems, the subretinal fluid does demark very well and the need for re-treatment is apparent,” says von der Burchard.

The team plans to continue developing their device, and study its imaging capabilities in more patients by asking clinicians to grade both full-field OCT and SD-OCT images (while being masked), and compare their image quality, which biomarkers are present, and  whether the patient needs anti-VEGF retreatment. “We believe that a hand-held OCT device would have a huge impact on alleviate disease burden, and may represent a paradigm shift in the treatment of wet AMD and other diseases.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. H Sudkamp et al., “In-vivo retinal imaging with off-axis full-field time-domain optical coherence tomography”, Opt Lett, 41, 4987–4990. PMID: 27805666.
About the Author
Ruth Steer

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register